Download PDF
CC BY-NC-ND 4.0 · Sports Med Int Open 2024; 08: a22831663
DOI: 10.1055/a-2283-1663
Review

Effects of Exercise-Induced Changes in Myokine Expression on the Tumor Microenvironment

Nadira Gunasekara 
1   Institute of Cardiology and Sports Medicine, German Sport University Cologne, Cologne, Germany
,
Dorothea Clauss
1   Institute of Cardiology and Sports Medicine, German Sport University Cologne, Cologne, Germany
,
Wilhelm Bloch
1   Institute of Cardiology and Sports Medicine, German Sport University Cologne, Cologne, Germany
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

In this narrative review, we summarize the direct and indirect effects that myokines have on the tumor microenvironment. We took studies of various cancer types and species into account. Systematic reviews and meta-analyses that matched the search terms were also considered. We searched databases for six months. As a narrative approach was chosen, no data was analyzed or reanalyzed. The goal of this narrative review is to create an overview on the topic to identify research gaps and answer the questions as to whether myokine expression may be relevant in cancer research in regard to the tumor microenvironment. Six commonly known myokines were chosen. We found strong links between the influence exercise has on interleukin-6, oncostatin M, secreted protein acidic and rich in cysteine, and irisin in the context of tumor progression and inhibition via interactions with the tumor microenvironment. It became clear that the effects of myokines on the tumor microenvironment can vary and contribute to disease progression or regression. Interactions among myokines and immune cells must also be considered and require further investigation. To date, no study has shown a clear connection, while multiple studies suggest further investigation of the topic, similar to the effects of exercise on myokine expression.

Keywords

interleukin-6 - oncostatin-m - irisin - SPARC - cancer


Publication History

Received: 10 October 2023
Received: 20 February 2024

Accepted: 26 April 2024

Accepted Manuscript online:
26 April 2024

Article published online:
19 June 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

Bibliographical Record
Nadira Gunasekara, Dorothea Clauss, Wilhelm Bloch. Effects of Exercise-Induced Changes in Myokine Expression on the Tumor Microenvironment. Sports Med Int Open 2024; 08: a22831663.
DOI: 10.1055/a-2283-1663
 

  • References

  • 1 Zhang X, Li Y, Liu D. Effects of exercise on the quality of life in breast cancer patients: a systematic review of randomized controlled trials. Support Care Cancer 2019; 27: 9-21 DOI: 10.1007/s00520-018-4363-2.
    Google Scholar
  • 2 Zhi X, Xie M, Zeng Y. et al. Effects of exercise intervention on quality of life in adolescent and young adult cancer patients and survivors: A meta-analysis. Integr Cancer Ther 2019; 18: 1534735419895590 DOI: 10.1177/1534735419895590.
    Google Scholar
  • 3 Liu Y-P, Hsiao M. Exercise-induced SPARC prevents tumorigenesis of colon cancer. Gut 2013; 62: 810-811 DOI: 10.1136/gutjnl-2012-303235.
    Google Scholar
  • 4 Cramp F, Byron-Daniel J. Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev 2012; 11: CD006145 DOI: 10.1002/14651858.CD006145.pub3.
    Google Scholar
  • 5 Casla S, Hojman P, Márquez-Rodas I. et al. Running away from side effects: physical exercise as a complementary intervention for breast cancer patients. Clin Transl Oncol 2015; 17: 180-196 DOI: 10.1007/s12094-014-1184-8.
    Google Scholar
  • 6 de Lima C, Alves LE, Iagher F. et al. Anaerobic exercise reduces tumor growth, cancer cachexia and increases macrophage and lymphocyte response in Walker 256 tumor-bearing rats. Eur J Appl Physiol 2008; 104: 957-964 DOI: 10.1007/s00421-008-0849-9.
    Google Scholar
  • 7 Spiliopoulou P, Gavriatopoulou M, Kastritis E. et al. Exercise-induced changes in tumor growth via tumor immunity. Sports (Basel) 2021; 9 -46 DOI: 10.3390/sports9040046.
    Google Scholar
  • 8 Wiggins JM, Opoku-Acheampong AB, Baumfalk DR. et al. Exercise and the tumor microenvironment: Potential therapeutic implications. Exerc Sport Sci Rev 2018; 46: 56-64 DOI: 10.1249/JES.0000000000000137.
    Google Scholar
  • 9 Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci 2012; 125: 5591-5596 DOI: 10.1242/jcs.116392.
    Google Scholar
  • 10 Anderson NM, Simon MC. The tumor microenvironment. Curr Biol 2020; 30: R921-R925 DOI: 10.1016/j.cub.2020.06.081.
    Google Scholar
  • 11 Arneth B. Tumor microenvironment. Medicina 2019; 56: 15 DOI: 10.3390/medicina56010015.
    Google Scholar
  • 12 Wu T, Dai Y. Tumor microenvironment and therapeutic response. Cancer Lett 2017; 387: 61-68 DOI: 10.1016/j.canlet.2016.01.043.
    Google Scholar
  • 13 Özdemir BH, Özdemir AA. How exercise affects the development and progression of hepatocellular carcinoma by changing the biomolecular status of the tumor microenvironment. Exp Clin Transplant 2022; Online Publication Date: Mar 15 2022 DOI: 10.6002/ect.2021.0456.
    Google Scholar
  • 14 Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008; 27: 5904-5912 DOI: 10.1038/onc.2008.271.
    Google Scholar
  • 15 Eschke RK, Lampit A, Schenk A. et al. Impact of physical exercise on growth and progression of cancer in rodents-A systematic review and meta-analysis. Front Oncol 2019; 9: 35 DOI: 10.3389/fonc.2019.00035.
    Google Scholar
  • 16 Pedersen L, Christensen JF, Hojman P. Effects of exercise on tumor physiology and metabolism. Cancer J 2015; 21: 111-116 DOI: 10.1097/PPO.0000000000000096.
    Google Scholar
  • 17 Pedersen BK. Exercise-induced myokines and their role in chronic diseases. Brain Behav Immun 2011; 25: 811-816 DOI: 10.1016/j.bbi.2011.02.010.
    Google Scholar
  • 18 Severinsen MCK, Pedersen BK. Muscle-organ crosstalk: The emerging roles of myokines. Endocr Rev 2020; 41: 594-609 DOI: 10.1210/endrev/bnaa016.
    Google Scholar
  • 19 Ruiz JR, Sui X, Lobelo F. et al. Muscular strength and adiposity as predictors of adulthood cancer mortality in men. Cancer Epidemiol Biomarkers Prev 2009; 18: 1468-1476 DOI: 10.1158/1055-9965.EPI-08-1075.
    Google Scholar
  • 20 Pedersen L, Hojman P. Muscle-to-organ cross talk mediated by myokines. Adipocyte 2012; 1: 164-167 DOI: 10.4161/adip.20344.
    Google Scholar
  • 21 Chen W, Wang L, You W. et al. Myokines mediate the cross talk between skeletal muscle and other organs. J Cell Physiol 2021; 236: 2393-2412 DOI: 10.1002/jcp.30033.
    Google Scholar
  • 22 Weigert C, Lehmann R, Hartwig S. et al. The secretome of the working human skeletal muscle--a promising opportunity to combat the metabolic disaster?. Proteomics Clin Appl 2014; 8: 5-18 DOI: 10.1002/prca.201300094.
    Google Scholar
  • 23 Ferrari R. Writing narrative style literature reviews. Med Writ 2015; 24: 230-235 DOI: 10.1179/2047480615Z.000000000329.
    Google Scholar
  • 24 Catoire M, Kersten S. The search for exercise factors in humans. FASEB J 2015; 29: 1615-1628 DOI: 10.1096/fj.14-263699.
    Google Scholar
  • 25 Brandt C, Pedersen BK. The role of exercise-induced myokines in muscle homeostasis and the defense against chronic diseases. J Biomed Biotechnol 2010; 2010: 520258 DOI: 10.1155/2010/520258.
    Google Scholar
  • 26 Sponder M, Campean I-A, Emich M. et al. Long-term endurance training increases serum cathepsin S and decreases IL-6 and hsCRP levels. J Sports Sci 2017; 35: 2129-2134 DOI: 10.1080/02640414.2016.1258482.
    Google Scholar
  • 27 Libardi CA, de Souza GV, Cavaglieri CR. et al. Effect of resistance, endurance, and concurrent training on TNF-α, IL-6, and CRP. Med Sci Sports Exerc 2012; 44: 50-56 DOI: 10.1249/MSS.0b013e318229d2e9.
    Google Scholar
  • 28 Prestes J, Shiguemoto G, Botero JP. et al. Effects of resistance training on resistin, leptin, cytokines, and muscle force in elderly post-menopausal women. J Sports Sci 2009; 27: 1607-1615 DOI: 10.1080/02640410903352923.
    Google Scholar
  • 29 Ostrowski K, Schjerling P, Pedersen BK. Physical activity and plasma interleukin-6 in humans--effect of intensity of exercise. Eur J Appl Physiol 2000; 83: 512-515 DOI: 10.1007/s004210000312.
    Google Scholar
  • 30 Kim J-S, Wilson RL, Taaffe DR. et al. Myokine expression and tumor-suppressive effect of serum after 12 wk of exercise in prostate cancer patients on ADT. Med Sci Sports Exerc 2022; 54: 197-205 DOI: 10.1249/MSS.0000000000002783.
    Google Scholar
  • 31 Kim J-S, Taaffe DR, Galvão DA. et al. Exercise in advanced prostate cancer elevates myokine levels and suppresses in-vitro cell growth. Prostate Cancer Prostatic Dis 2022; 25: 86-92 DOI: 10.1038/s41391-022-00504-x.
    Google Scholar
  • 32 Dobashi S, Hashimoto M, Koyama K. et al. Impact of acute resistance exercise on circulating secreted protein acidic and rich in cysteine (SPARC) levels in healthy young males: A pilot study. Sci Sports 2021; 36: 492-494 DOI: 10.1016/j.scispo.2020.12.005.
    Google Scholar
  • 33 Songsorn P, Ruffino J, Vollaard NBJ. No effect of acute and chronic supramaximal exercise on circulating levels of the myokine SPARC. Eur J Sport Sci 2017; 17: 447-452 DOI: 10.1080/17461391.2016.1266392.
    Google Scholar
  • 34 Nygaard H, Slettaløkken G, Vegge G. et al. Irisin in blood increases transiently after single sessions of intense endurance exercise and heavy strength training. PLoS One 2015; 10: e0121367 DOI: 10.1371/journal.pone.0121367.
    Google Scholar
  • 35 Colpitts BH, Rioux BV, Eadie AL. et al. Irisin response to acute moderate intensity exercise and high intensity interval training in youth of different obesity statuses: A randomized crossover trial. Physiol Rep 2022; 10: e15198 DOI: 10.14814/phy2.15198.
    Google Scholar
  • 36 Hecksteden A, Wegmann M, Steffen A. et al. Irisin and exercise training in humans - results from a randomized controlled training trial. BMC Med 2013; 11: 235 DOI: 10.1186/1741-7015-11-235.
    Google Scholar
  • 37 Arazi H, Babaei P, Moghimi M. et al. Acute effects of strength and endurance exercise on serum BDNF and IGF-1 levels in older men. BMC Geriatr 2021; 21: 50 DOI: 10.1186/s12877-020-01937-6.
    Google Scholar
  • 38 Gaitán JM, Moon HY, Stremlau M. et al. Effects of aerobic exercise training on systemic biomarkers and cognition in late middle-aged adults at risk for Alzheimer's disease. Front Endocrinol 2021; 12: 660181 DOI: 10.3389/fendo.2021.660181.
    Google Scholar
  • 39 Coelho-Júnior HJ, Gonçalves IO, Sampaio RAC. et al. Effects of combined resistance and power training on cognitive function in older women: A randomized controlled trial. Int J Environ Res Public Health 2020; 17: 3435 DOI: 10.3390/ijerph17103435.
    Google Scholar
  • 40 Scheller J, Chalaris A, Schmidt-Arras D. et al. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 2011; 1813: 878-888 DOI: 10.1016/j.bbamcr.2011.01.034.
    Google Scholar
  • 41 Fisher DT, Appenheimer MM, Evans SS. The two faces of IL-6 in the tumor microenvironment. Semin Immunol 2014; 26: 38-47 DOI: 10.1016/j.smim.2014.01.008.
    Google Scholar
  • 42 Gabay C. Interleukin-6 and chronic inflammation. Arthritis Res Ther 2006; 8: S3 DOI: 10.1186/ar1917.
    Google Scholar
  • 43 Kang S, Tanaka T, Narazaki M. et al. Targeting interleukin-6 signaling in clinic. Immunity 2019; 50: 1007-1023 DOI: 10.1016/j.immuni.2019.03.026.
    Google Scholar
  • 44 Abdulrauf SI, Edvardsen K, Ho KL. et al. Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma. J Neurosurg 1998; 88: 513-520 DOI: 10.3171/jns.1998.88.3.0513.
    Google Scholar
  • 45 Ruoslahti E. Specialization of tumour vasculature. Nat Rev Cancer 2002; 2: 83-90 DOI: 10.1038/nrc724.
    Google Scholar
  • 46 Schaaf MB, Garg AD, Agostinis P. Defining the role of the tumor vasculature in antitumor immunity and immunotherapy. Cell Death Dis 2018; 9: 115 DOI: 10.1038/s41419-017-0061-0.
    Google Scholar
  • 47 Wei L-H, Kuo M-L, Chen C-A. et al. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene 2003; 22: 1517-1527 DOI: 10.1038/sj.onc.1206226.
    Google Scholar
  • 48 Kumari N, Dwarakanath BS, Das A. et al. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumor Biol 2016; 37: 11553-11572 DOI: 10.1007/s13277-016-5098-7.
    Google Scholar
  • 49 Kistner TM, Pedersen BK, Lieberman DE. Interleukin 6 as an energy allocator in muscle tissue. Nat Metab 2022; 4: 170-179 DOI: 10.1038/s42255-022-00538-4.
    Google Scholar
  • 50 Orange ST, Jordan AR, Odell A. et al. Acute aerobic exercise-conditioned serum reduces colon cancer cell proliferation in vitro through interleukin-6-induced regulation of DNA damage. Int J Cancer 2022; 151: 265-274 DOI: 10.1002/ijc.33982.
    Google Scholar
  • 51 Procházka V, Papajík T, Faber E. et al. Soluble interleukin-2 receptor level predicts survival in patients with follicular lymphoma treated with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy in the rituximab era. Leuk Lymphoma 2014; 55: 1584-1590 DOI: 10.3109/10428194.2013.850167.
    Google Scholar
  • 52 Gu F-M, Li Q-L, Gao Q. et al. IL-17 induces AKT-dependent IL-6/JAK2/STAT3 activation and tumor progression in hepatocellular carcinoma. Mol Cancer 2011; 10: 150 DOI: 10.1186/1476-4598-10-150.
    Google Scholar
  • 53 Sehgal PB. Interleukin-6 at the host-tumor interface: STAT3 in biomolecular condensates in cancer cells. Cells 2022; 11: 1164 DOI: 10.3390/cells11071164.
    Google Scholar
  • 54 Lin Y, He Z, Ye J. et al. Progress in understanding the IL-6/STAT3 pathway in colorectal cancer. Onco Targets Ther 2020; 13: 13023-13032 DOI: 10.2147/OTT.S278013.
    Google Scholar
  • 55 Wang L, Zhang F, Cui J-Y. et al. CAFs enhance paclitaxel resistance by inducing EMT through the IL‑6/JAK2/STAT3 pathway. Oncol Rep 2018; 39: 2081-2090 DOI: 10.3892/or.2018.6311.
    Google Scholar
  • 56 Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 2005; 17: 548-558 DOI: 10.1016/j.ceb.2005.08.001.
    Google Scholar
  • 57 Wang Y, Zhou BP. Epithelial-mesenchymal transition in breast cancer progression and metastasis. Chin J Cancer 2011; 30: 603-611 DOI: 10.5732/cjc.011.10226.
    Google Scholar
  • 58 Zhang P, Sun Y, Ma L. ZEB1: at the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance. Cell Cycle 2015; 14: 481-487 DOI: 10.1080/15384101.2015.1006048.
    Google Scholar
  • 59 Gonzalez DM, Medici D. Signaling mechanisms of the epithelial-mesenchymal transition. Sci Signal 2014; 7: re8 DOI: 10.1126/scisignal.2005189.
    Google Scholar
  • 60 Sullivan NJ, Sasser AK, Axel AE. et al. Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene 2009; 28: 2940-2947 DOI: 10.1038/onc.2009.180.
    Google Scholar
  • 61 Cheteh EH, Sarne V, Ceder S. et al. Interleukin-6 derived from cancer-associated fibroblasts attenuates the p53 response to doxorubicin in prostate cancer cells. Cell Death Discov 2020; 6: 42 DOI: 10.1038/s41420-020-0272-5.
    Google Scholar
  • 62 Ene C-V, Nicolae I, Geavlete B. et al. IL-6 Signaling link between inflammatory tumor microenvironment and prostatic tumorigenesis. Anal Cell Pathol (Amst) 2022; 2022: 5980387 DOI: 10.1155/2022/5980387.
    Google Scholar
  • 63 Bousso P, Robey E. Dynamics of CD8+ T cell priming by dendritic cells in intact lymph nodes. Nat Immunol 2003; 4: 579-585 DOI: 10.1038/ni928.
    Google Scholar
  • 64 Rundqvist H, Veliça P, Barbieri L. et al. Cytotoxic T-cells mediate exercise-induced reductions in tumor growth. Elife 2020; 9: e59996 DOI: 10.7554/eLife.59996.
    Google Scholar
  • 65 Yang R, Masters AR, Fortner KA. et al. IL-6 promotes the differentiation of a subset of naive CD8+ T cells into IL-21-producing B helper CD8+ T cells. J Exp Med 2016; 213: 2281-2291 DOI: 10.1084/jem.20160417.
    Google Scholar
  • 66 Nakagawa T, Tsuruoka M, Ogura H. et al. IL-6 positively regulates Foxp3+CD8+ T cells in vivo. Int Immunol 2010; 22: 129-139 DOI: 10.1093/intimm/dxp119.
    Google Scholar
  • 67 Hsieh C-C, Hung C-H, Chiang M. et al. Hepatic stellate cells enhance liver cancer progression by inducing myeloid-derived suppressor cells through interleukin-6 signaling. Int J Mol Sci 2019; 20: 5079 DOI: 10.3390/ijms20205079.
    Google Scholar
  • 68 Gulubova MV, Chonov DC, Ivanova KV. et al. Intratumoural expression of IL-6/STAT3, IL-17 and FOXP3 immune cells in the immunosuppressive tumour microenvironment of colorectal cancer immune cells-positive for IL-6, STAT3, IL-17 and FOXP3 and colorectal cancer development. Biotechnol Biotechnol Equip 2022; 36: 327-338 DOI: 10.1080/13102818.2022.2072765.
    Google Scholar
  • 69 Pedersen L, Idorn M, Olofsson GH. et al. Voluntary running suppresses tumor growth through epinephrine- and IL-6-dependent NK cell mobilization and redistribution. Cell Metab 2016; 23: 554-562 DOI: 10.1016/j.cmet.2016.01.011.
    Google Scholar
  • 70 Queen MM, Ryan RE, Holzer RG. et al. Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression. Cancer Res 2005; 65: 8896-8904 DOI: 10.1158/0008-5472.CAN-05-1734.
    Google Scholar
  • 71 Richards CD, Botelho F. Oncostatin M in the regulation of connective tissue cells and macrophages in pulmonary disease. Biomedicines 2019; 7: 95 DOI: 10.3390/biomedicines7040095.
    Google Scholar
  • 72 Won Seok Hyung W, Gon Lee S, Tae Kim K. et al. Oncostatin M, a muscle-secreted myokine, recovers high-glucose-induced impairment of Akt phosphorylation by Fos induction in hippocampal neuron cells. Neuroreport 2019; 30: 765-770 DOI: 10.1097/WNR.0000000000001271.
    Google Scholar
  • 73 Komori T, Morikawa Y. Essential roles of the cytokine oncostatin M in crosstalk between muscle fibers and immune cells in skeletal muscle after aerobic exercise. J Biol Chem 2022; 298: 102686 DOI: 10.1016/j.jbc.2022.102686.
    Google Scholar
  • 74 Masjedi A, Hajizadeh F, Beigi Dargani F. et al. Oncostatin M: A mysterious cytokine in cancers. Int Immunopharmacol 2021; 90: 107158 DOI: 10.1016/j.intimp.2020.107158.
    Google Scholar
  • 75 Caligiuri A, Gitto S, Lori G. et al. Oncostatin M: From intracellular signaling to therapeutic targets in liver cancer. Cancers (Basel) 2022; 14: 4211 DOI: 10.3390/cancers14174211.
    Google Scholar
  • 76 Karimi F, Behboudi Tabrizi L. The effects of six weeks of aerobic training on the tumor volume and oncostatin-M serum level in mice with breast cancer. J Res Med Sci 2018; 17: 105-114
    Google Scholar
  • 77 Caffarel MM, Coleman N. Oncostatin M receptor is a novel therapeutic target in cervical squamous cell carcinoma. J Pathol 2014; 232: 386-390 DOI: 10.1002/path.4305.
    Google Scholar
  • 78 Junk DJ, Bryson BL, Smigiel JM. et al. Oncostatin M promotes cancer cell plasticity through cooperative STAT3-SMAD3 signaling. Oncogene 2017; 36: 4001-4013 DOI: 10.1038/onc.2017.33.
    Google Scholar
  • 79 Fuxe J, Vincent T, Garcia de Herreros A. Transcriptional crosstalk between TGF-β and stem cell pathways in tumor cell invasion: role of EMT promoting Smad complexes. Cell Cycle 2010; 9: 2363-2374 DOI: 10.4161/cc.9.12.12050.
    Google Scholar
  • 80 Simonneau M, Frouin E, Huguier V. et al. Oncostatin M is overexpressed in skin squamous-cell carcinoma and promotes tumor progression. Oncotarget 2018; 9: 36457-36473 DOI: 10.18632/oncotarget.26355.
    Google Scholar
  • 81 Araujo AM, Abaurrea A, Azcoaga P. et al. Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment. J Clin Invest 2022; 132 DOI: 10.1172/JCI148667.
    Google Scholar
  • 82 Kim MK, Kim Y, Park S. et al. Effects of steady low-intensity exercise on high-fat diet stimulated breast cancer progression via the alteration of macrophage polarization. Integr Cancer Ther 2020; 19: 1534735420949678 DOI: 10.1177/1534735420949678.
    Google Scholar
  • 83 Porter PL, Sage EH, Lane TF. et al Distribution of SPARC in normal and neoplastic human tissue. J Histochem Cytochem 995 43: 791-800 DOI: 10.1177/43.8.7622842.
    Google Scholar
  • 84 Clark CJ, Sage EH. A prototypic matricellular protein in the tumor microenvironment--where there's SPARC, there's fire. J Cell Biochem 2008; 104: 721-732 DOI: 10.1002/jcb.21688.
    Google Scholar
  • 85 Arnold SA, Brekken RA. SPARC: a matricellular regulator of tumorigenesis. J Cell Commun Signal 2009; 3: 255-273 DOI: 10.1007/s12079-009-0072-4.
    Google Scholar
  • 86 Nagaraju GPC, Sharma D. Anti-cancer role of SPARC, an inhibitor of adipogenesis. Cancer Treat Rev 2011; 37: 559-566 DOI: 10.1016/j.ctrv.2010.12.001.
    Google Scholar
  • 87 Ledda MF, Adris S, Bravo AI. et al. Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nat Med 1997; 3: 171-176 DOI: 10.1038/nm0297-171.
    Google Scholar
  • 88 Said N, Frierson HF, Sanchez-Carbayo M. et al. Loss of SPARC in bladder cancer enhances carcinogenesis and progression. J Clin Invest 2013; 123: 751-766 DOI: 10.1172/JCI64782.
    Google Scholar
  • 89 Vaz J, Ansari D, Sasor A. et al. SPARC: A potential prognostic and therapeutic target in pancreatic cancer. Pancreas 2015; 44: 1024-1035 DOI: 10.1097/MPA.0000000000000409.
    Google Scholar
  • 90 Liang J, Wang H, Xiao H. et al. Relationship and prognostic significance of SPARC and VEGF protein expression in colon cancer. J Exp Clin Cancer Res 2010; 29: 71 DOI: 10.1186/1756-9966-29-71.
    Google Scholar
  • 91 Bao J-M, Dang Q, Lin C-J. et al. SPARC is a key mediator of TGF-β-induced renal cancer metastasis. J Cell Physiol 2021; 236: 1926-1938 DOI: 10.1002/jcp.29975.
    Google Scholar
  • 92 Said N, Socha MJ, Olearczyk JJ. et al. Normalization of the ovarian cancer microenvironment by SPARC. Mol Cancer Res 2007; 5: 1015-1030 DOI: 10.1158/1541-7786.MCR-07-0001.
    Google Scholar
  • 93 Boström P, Wu J, Jedrychowski MP. et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 2012; 481: 463-468 DOI: 10.1038/nature10777.
    Google Scholar
  • 94 Cebulski K, Nowińska K, Jablońska K. et al. Expression of irisin/FNDC5 in breast cancer. Int J Mol Sci 2022; 23: 3530 DOI: 10.3390/ijms23073530.
    Google Scholar
  • 95 Maak S, Norheim F, Drevon CA. et al. Progress and challenges in the biology of FNDC5 and irisin. Endocr Rev 2021; 42: 436-456 DOI: 10.1210/endrev/bnab003.
    Google Scholar
  • 96 Maalouf G-E, El Khoury D. Exercise-induced irisin, the fat browning myokine, as a potential anticancer agent. J Obes 2019; 2019: 6561726 DOI: 10.1155/2019/6561726.
    Google Scholar
  • 97 Tsai C-L, Pan C-Y, Tseng Y-T. et al. Acute effects of high-intensity interval training and moderate-intensity continuous exercise on BDNF and irisin levels and neurocognitive performance in late middle-aged and older adults. Behav Brain Res 2021; 413: 113472 DOI: 10.1016/j.bbr.2021.113472.
    Google Scholar
  • 98 Tsuchiya Y, Ando D, Takamatsu K. et al. Resistance exercise induces a greater irisin response than endurance exercise. Metabolism 2015; 64: 1042-1050 DOI: 10.1016/j.metabol.2015.05.010.
    Google Scholar
  • 99 Qiu S, Cai X, Sun Z. et al. Chronic exercise training and circulating irisin in adults: A meta-analysis. Sports Med 2015; 45: 1577-1588 DOI: 10.1007/s40279-014-0293-4.
    Google Scholar
  • 100 Polyzos SA, Anastasilakis AD, Efstathiadou ZA. et al. Irisin in metabolic diseases. Endocrine 2018; 59: 260-274 DOI: 10.1007/s12020-017-1476-1.
    Google Scholar
  • 101 Altay DU, Keha EE, Karagüzel E. et al. The diagnostic value of FNDC5/irisin in renal cell cancer. Int Braz J Urol 2018; 44: 734-739 DOI: 10.1590/S1677-5538.IBJU.2017.0404.
    Google Scholar
  • 102 Nowinska K, Jablonska K, Pawelczyk K. et al. Expression of irisin/FNDC5 in cancer cells and stromal fibroblasts of non-small cell lung cancer. Cancers (Basel) 2019; 11: 1538 DOI: 10.3390/cancers11101538.
    Google Scholar
  • 103 Alizadeh Zarei M, Seyed Hosseini E, Haddad Kashani H. et al. Effects of the exercise-inducible myokine irisin on proliferation and malignant properties of ovarian cancer cells through the HIF-1 α signaling pathway. Sci Rep 2023; 13: 170 DOI: 10.1038/s41598-022-26700-2.
    Google Scholar
  • 104 Gannon NP, Vaughan RA, Garcia-Smith R. et al. Effects of the exercise-inducible myokine irisin on malignant and non-malignant breast epithelial cell behavior in vitro. Int J Cancer 2015; 136: E197-E202 DOI: 10.1002/ijc.29142.
    Google Scholar
  • 105 Shim MK, Yoon HY, Lee S. et al. Caspase-3/-7-specific metabolic precursor for bioorthogonal tracking of tumor apoptosis. Sci Rep 2017; 7: 16635 DOI: 10.1038/s41598-017-16653-2.
    Google Scholar
  • 106 Dolcet X, Llobet D, Pallares J. et al. NF-kB in development and progression of human cancer. Virchows Arch 2005; 446: 475-482 DOI: 10.1007/s00428-005-1264-9.
    Google Scholar
  • 107 Yang BC, Leung PS. Irisin Is a positive regulator for ferroptosis in pancreatic cancer. Mol Ther Oncolytics 2020; 18: 457-466 DOI: 10.1016/j.omto.2020.08.002.
    Google Scholar
  • 108 Löffler D, Müller U, Scheuermann K. et al. Serum irisin levels are regulated by acute strenuous exercise. J Clin Endocrinol Metab 2015; 100: 1289-1299 DOI: 10.1210/jc.2014-2932.
    Google Scholar
  • 109 Shimizu E, Hashimoto K, Okamura N. et al. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biological Psychiatry 2003; 54: 70-75 DOI: 10.1016/S0006-3223(03)00181-1.
    Google Scholar
  • 110 Fulgenzi G, Hong Z, Tomassoni-Ardori F. et al. Novel metabolic role for BDNF in pancreatic β-cell insulin secretion. Nat Commun 2020; 11: 1950 DOI: 10.1038/s41467-020-15833-5.
    Google Scholar
  • 111 de Lima NS, De Sousa RAL, Amorim FT. et al. Moderate-intensity continuous training and high-intensity interval training improve cognition, and BDNF levels of middle-aged overweight men. Metab Brain Dis 2022; 37: 463-471 DOI: 10.1007/s11011-021-00859-5.
    Google Scholar
  • 112 Matthews VB, Aström M-B, Chan MHS. et al. Brain-derived neurotrophic factor is produced by skeletal muscle cells in response to contraction and enhances fat oxidation via activation of AMP-activated protein kinase. Diabetologia 2009; 52: 1409-1418 DOI: 10.1007/s00125-009-1364-1.
    Google Scholar
  • 113 Malekan M, Nezamabadi SS, Samami E. et al. BDNF and its signaling in cancer. J Cancer Res Clin Oncol 2023; 149: 2621-2636 DOI: 10.1007/s00432-022-04365-8.
    Google Scholar